This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer’s disease: a retrospective analysis


Cummings, Jeffrey L., Ferris, Steven H., Farlow, Martin R., Olin, Jason T., Meng, Xiangyi


Dementia And Geriatric Cognitive Disorders, Volume: 29, No.: 5, Pages.: 406-412

Year of Publication



Background: The Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) scale is widely used in Alzheimer trials. It assesses cognition, activities of daily living (ADLs), behavior and global functioning. To advance the understanding of relationships between the ADCS-CGIC and scores from other commonly used tools, this analysis investigated the ability of each domain to measure change. This was a hypothesis-forming study, designed to provide a basis for possible future research.; Methods: This retrospective analysis used data from a 24-week, randomized, placebo-controlled trial [study ENA713D2320 (IDEAL)] that evaluated rivastigmine patches and capsules in AD patients.; Results: At week 24, significant treatment effects versus placebo were seen on the ADCS-CGIC cognitive domain with rivastigmine 17.4 mg/24 h patch (p < 0.01), 9.5 mg/24 h patch (p = 0.02) and capsules (p < 0.01); similarly on the ADCS-CGIC ADL domain. The cognition portion of the CGIC correlated with the Alzheimer's Disease Assessment Scale cognitive subscale and the ADL section with the ADCS-ADL trial measures. Variance ascribable to these tools was small, indicating that CGIC detects changes not measured by the domain-specific tools.; Conclusions: The results of this post hoc analysis suggest that the ADCS-CGIC accurately reflects changes in cognitive and functional domains measured by other tools; it captures changes not assessed by domain-specific instruments. Cognitive alterations show greatest correlation with total CGIC. These results may assist in analyzing and interpreting CGIC results in other trials.;

Bibtex Citation

@article{Cummings_2010, doi = {10.1159/000296073}, url = {}, year = 2010, publisher = {S. Karger {AG}}, volume = {29}, number = {5}, pages = {406--412}, author = {Jeffrey L. Cummings and Steven H. Ferris and Martin R. Farlow and Jason T. Olin and Xiangyi Meng}, title = {Effects of Rivastigmine Transdermal Patch and Capsule on Aspects of Clinical Global Impression of Change in Alzheimer's Disease: A Retrospective Analysis}, journal = {Dementia and Geriatric Cognitive Disorders} }


174, administration & dosage, administration cutaneous, administration oral, aged, aged, 80 and over, alzheimer disease, behavior, capsules, double-blind method, drug therapy, female, h, humans, male, mental processes, mg24, middle aged, neuroprotective agents, neuropsychological tests, patch, phenylcarbamates, psychology, randomized controlled trials as topic, retrospective studies, rivastigmine, therapeutic use, treatment outcome

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Instrument development and testing (cross walking of measures, etc.), Randomised Controlled Trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime